어플

Koo Kwang-mo visited Toronto, Canada, to look at market trends in future business areas in bio and artificial intelligence (AI).

Business / 김지선 / 08/25/2023 03:18 AM
 

 

[Alpha Biz=(Chicago) Reporter Kim Jisun] According to LG on the 24th, Chairman Koo visited LG Chem Life Science Headquarters' Boston subsidiary (Innovation Center), US pharmaceutical company AVEO, which LG Chem acquired this year, and LG Electronics' Toronto AI Lab (Lab) for four days from the 21st (local time).

Chairman Koo first met with LG Chem Life Sciences head Sohn Ji-woong, Boston branch head Lee Dong-soo and CEO Michael Bailey Abeo at the Boston Innovation Center to examine the direction of the new drug business and ways to strengthen global commercialization capabilities and discuss strategies to foster them.

Koo examined strategies for developing innovative new drugs such as anti-cancer drugs and cell therapy drugs, and also looked at the status of strengthening business competitiveness after the acquisition of Abeo.

LG Chem's Life Sciences Division is speeding up its entry into the U.S. market, which accounts for more than half of the global innovative new drug market. The goal is to become a global top-tier pharmaceutical company by 2030.

 

 

AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)

Related articles

[Exclusive] Samsung Electronics to Supply HBM3E 12-High Stacks to NVIDIA
DL E&C Executives Resign En Masse Following Fatal Construction Site Accident
POSCO Future M Terminates KRW 945 Billion ESS Cathode Material Supply Contract, Signs New LFP Partnership with CNGR
Hahn & Company Selects TKG Taekwang as Preferred Bidder for Sale of Semiconductor Parts Maker Solmix
Hyundai Motor Group Bolsters SDV and Autonomous Driving Capabilities with KRW 500.3 Billion Investment in 42dot
comments >

SNS